Weixia Chong, Wei Fu. Advances in clinical application of residual radioactivity measurment method in patients with differentiated thyroid cancer surgery after 131I treatment[J]. Int J Radiat Med Nucl Med, 2022, 46(1): 42-46. DOI: 10.3760/cma.j.cn121381-202105005-00131
Citation: Weixia Chong, Wei Fu. Advances in clinical application of residual radioactivity measurment method in patients with differentiated thyroid cancer surgery after 131I treatment[J]. Int J Radiat Med Nucl Med, 2022, 46(1): 42-46. DOI: 10.3760/cma.j.cn121381-202105005-00131

Advances in clinical application of residual radioactivity measurment method in patients with differentiated thyroid cancer surgery after 131I treatment

  • According to different risk stratification results of differentiated thyroid cancer (DTC) patients after surgery, some patients may need further 131I treatment, but 131I can emit radiation to the surrounding population. Therefore, the correct assessment of radiation dose in patients is crucial to the individualization of radiation protection and the optimization of 131I treatment process. For the measurement method of radiation dose during 131I treatment after DTC, there are mainly two types, which are in vivo and in vitro. In vitro measurements include urine and blood measurement methods; in vivo measurements mainly include local and systemic measurement methods. The authors mainly discuss dose-related measurement methods and clinical application.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return